Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing.

Neisseria meningitidis is a major cause of bacterial septicemia and meningitis. Sequence variation of surface-exposed proteins and cross-reactivity of the serogroup B capsular polysaccharide with human tissues have hampered efforts to develop a successful vaccine. To overcome these obstacles, the entire genome sequence of a virulent serogroup B strain (MC58) was used to identify vaccine candidates. A total of 350 candidate antigens were expressed in Escherichia coli, purified, and used to immunize mice. The sera allowed the identification of proteins that are surface exposed, that are conserved in sequence across a range of strains, and that induce a bactericidal antibody response, a property known to correlate with vaccine efficacy in humans.

[1]  S. Salzberg,et al.  Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. , 2000, Science.

[2]  Antigenic Variation of the Class I Outer Membrane Protein in Hyperendemic Neisseria meningitidis Strains in The Netherlands , 1999, Infection and Immunity.

[3]  J. Tappero,et al.  Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. , 1999, JAMA.

[4]  J. M. Smith,et al.  Free recombination within Helicobacter pylori. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[5]  J. M. Smith,et al.  Detecting recombination from gene trees. , 1998, Molecular biology and evolution.

[6]  M. Achtman,et al.  Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[7]  J. Höltje,et al.  Growth of the Stress-Bearing and Shape-Maintaining Murein Sacculus of Escherichia coli , 1998, Microbiology and Molecular Biology Reviews.

[8]  A. Schuchat,et al.  Bacterial Meningitis in the United States in 1995 , 1997 .

[9]  W. Vollmer,et al.  Outer membrane localization of murein hydrolases: MltA, a third lipoprotein lytic transglycosylase in Escherichia coli , 1997, Journal of bacteriology.

[10]  N. Cadieux,et al.  Highly Conserved Neisseria meningitidis Surface Protein Confers Protection against Experimental Infection , 1997, The Journal of experimental medicine.

[11]  R. Rappuoli,et al.  Meningococcal polysaccharide-protein conjugate vaccines , 1997 .

[12]  J. S. St. Geme,et al.  Characterization of the genetic locus encoding Haemophilus influenzae type b surface fibrils , 1996, Journal of bacteriology.

[13]  R. Reinhardt,et al.  Allelic polymorphism and site‐specific recombination in the opc locus of Neisseria meningitidis , 1996, Molecular microbiology.

[14]  D. Granoff,et al.  Complement-mediated bactericidal activity of human antibodies to poly alpha 2-->8 N-acetylneuraminic acid, the capsular polysaccharide of Neisseria meningitidis serogroup B. , 1995, The Journal of infectious diseases.

[15]  G. Rougon,et al.  Antibodies to polysialic acid and its N-propyl derivative: binding properties and interaction with human embryonal brain glycopeptides. , 1995, The Journal of infectious diseases.

[16]  Poolman Jt.  Development of a meningococcal vaccine. , 1995 .

[17]  M. Achtman,et al.  Antigenic and epidemiologic properties of the ET-37 complex of Neisseria meningitidis. , 1993, The Journal of infectious diseases.

[18]  W. Goebel,et al.  The iap gene of Listeria monocytogenes is essential for cell viability, and its gene product, p60, has bacteriolytic activity , 1993, Journal of bacteriology.

[19]  H. Valkenburg,et al.  Meningococcal disease in The Netherlands, 1958-1990: a steady increase in the incidence since 1982 partially caused by new serotypes and subtypes of Neisseria meningitidis. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  C. Sacchi,et al.  Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil , 1992, The Lancet.

[21]  P. A. van der Ley,et al.  Construction of a multivalent meningococcal vaccine strain based on the class 1 outer membrane protein , 1992, Infection and immunity.

[22]  A. Halstensen,et al.  Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway , 1991, The Lancet.

[23]  S. Kathariou,et al.  Insertion of Tn916 in Neisseria meningitidis resulting in loss of group B capsular polysaccharide , 1991, Infection and immunity.

[24]  J. Cannon,et al.  Physical map of the chromosome of Neisseria gonorrhoeae FA1090 with locations of genetic markers, including opa and pil genes , 1991, Journal of bacteriology.

[25]  A. Barlow,et al.  Point mutation in meningococcal por A gene associated with increased endemic disease , 1991, The Lancet.

[26]  J. Dixon,et al.  Eukaryotic proteins expressed in Escherichia coli: an improved thrombin cleavage and purification procedure of fusion proteins with glutathione S-transferase. , 1991, Analytical biochemistry.

[27]  S. Moseley,et al.  Contribution of a 28-kilodalton membrane protein to the virulence of Haemophilus influenzae , 1991, Infection and immunity.

[28]  S. Borriello,et al.  Comparison of methods for the analysis of outer membrane antigens of Neisseria meningitidis by western blotting. , 1990, Journal of immunological methods.

[29]  R. Rappuoli,et al.  Filamentous hemagglutinin of Bordetella pertussis: nucleotide sequence and crucial role in adherence. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[30]  D. Bitter‐Suermann,et al.  An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues. , 1987, Journal of immunology.

[31]  D. Caugant,et al.  Genetic structure of Neisseria meningitidis populations in relation to serogroup, serotype, and outer membrane protein pattern , 1987, Journal of bacteriology.

[32]  M. Artenstein,et al.  HUMAN IMMUNITY TO THE MENINGOCOCCUS IV. IMMUNOGENICITY OF GROUP A AND GROUP C MENINGOCOCCAL POLYSACCHARIDES IN HUMAN VOLUNTEERS , 1969 .

[33]  M. Artenstein,et al.  HUMAN IMMUNITY TO THE MENINGOCOCCUS I. THE ROLE OF HUMORAL ANTIBODIES , 1969 .

[34]  M. Artenstein,et al.  HUMAN IMMUNITY TO THE MENINGOCOCCUS : III. PREPARATION AND IMMUNOCHEMICAL PROPERTIES OF THE GROUP A, GROUP B, AND GROUP C MENINGOCOCCAL POLYSACCHARIDES , 1969 .